A glucagon-based dual agonist in the next wave of metabolic peptide research.
Also known as: BI 456906 · EX-A7878
Part of the Metabolic & GLP-1 peptides cluster
Overview
Survodutide (BI 456906) is an investigational dual GLP-1 and glucagon receptor agonist studied in metabolic and liver research. Unlike many peers, it is engineered on a glucagon backbone rather than oxyntomodulin. It is not an approved or Health Canada-authorized therapeutic.
Source & context
Biological / chemical source: Synthetic acylated peptide (Boehringer Ingelheim)
Primary research or clinical context: Investigational compound in clinical development; not authorized by Health Canada
Dual-receptor design
Survodutide is described in the literature as engaging both the GLP-1 and glucagon receptors. Researchers are interested in whether adding glucagon-receptor activity to incretin signaling changes energy expenditure and hepatic pathways compared with GLP-1-only agonists. The exact residue count and acylation details are proprietary and not fully public.
Research context
Because it targets two receptors, survodutide is often discussed alongside tirzepatide, retatrutide, and mazdutide in comparisons of single, dual, and triple agonists. Reported studies have examined metabolic and liver endpoints, but readers should treat social-media summaries cautiously and prioritize peer-reviewed and registry data.
Regulatory status
Survodutide remains an investigational molecule and is not authorized for sale as a medicine in Canada. This page is educational and does not provide dosing, protocols, or treatment advice.
FAQ about Survodutide
What is Survodutide?+
Survodutide (BI 456906) is an investigational dual GLP-1 and glucagon receptor agonist studied in metabolic and liver research. Unlike many peers, it is engineered on a glucagon backbone rather than oxyntomodulin. It is not an approved or Health Canada-authorized therapeutic.
Is Survodutide an approved medicine?+
Survodutide is discussed here as a research / educational topic. Investigational compound in clinical development; not authorized by Health Canada. This is not medical advice.
What is the typical length of Survodutide?+
Survodutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.